2018

adalimumab

  • Development
  • Preclinical Studies
  • I Phase
  • II Phase
  • III Phase
  • Registration
2018

darbepoetin alfa

  • Development
  • Preclinical Studies
  • I Phase
  • II Phase
  • III Phase
  • Registration
2019

anti IL-17 mAb

  • Development
  • Preclinical Studies
  • I Phase
  • II Phase
  • III Phase
  • Registration
2019

anti PD-1 mAb

  • Development
  • Preclinical Studies
  • I Phase
  • II Phase
  • III Phase
  • Registration
2019

CDK8 inhibitor

  • Development
  • Preclinical Studies
  • I Phase
  • II Phase
  • III Phase
  • Registration
2020

Tenexia® (pegylated interferon beta-1a)

  • Development
  • Preclinical Studies
  • I Phase
  • II Phase
  • III Phase
  • Registration
2020

anti IL-6R mAb

  • Development
  • Preclinical Studies
  • I Phase
  • II Phase
  • III Phase
  • Registration
2020

pegylated darbepoetin alfa

  • Development
  • Preclinical Studies
  • I Phase
  • II Phase
  • III Phase
  • Registration
2020

ANTI CTLA4 MAB

  • Development
  • Preclinical Studies
  • I Phase
  • II Phase
  • III Phase
  • Registration
2021

anti PD-L1 mAb

  • Development
  • Preclinical Studies
  • I Phase
  • II Phase
  • III Phase
  • Registration
2023

anti PCSK9 mAb

  • Development
  • Preclinical Studies
  • I Phase
  • II Phase
  • III Phase
  • Registration
2023

anti CD47 mAb

  • Development
  • Preclinical Studies
  • I Phase
  • II Phase
  • III Phase
  • Registration
2023

anti CD20 mAb

  • Development
  • Preclinical Studies
  • I Phase
  • II Phase
  • III Phase
  • Registration
2023

anti CD20 mAb

  • Development
  • Preclinical Studies
  • I Phase
  • II Phase
  • III Phase
  • Registration
2023

anti IL-5R mAb

  • Development
  • Preclinical Studies
  • I Phase
  • II Phase
  • III Phase
  • Registration
2023

anti C-MET mAb

  • Development
  • Preclinical Studies
  • I Phase
  • II Phase
  • III Phase
  • Registration